Innoviva (INVA) Free Cash Flow (2010 - 2026)
Innoviva posted quarterly Free Cash Flow of $34.8 million for Q1 2026, down 28.44% year-on-year from $48.6 million in Q1 2025, and down 75.38% on a QoQ basis from $141.3 million in Q3 2025.
Innoviva (INVA) has 17 years of Free Cash Flow data on file, last reported at $34.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 28.44% year-over-year to $34.8 million; the trailing twelve-month figure through Mar 2026 stood at $220.2 million (down 0.61% YoY), and the FY2025 full-year result was $195.8 million, up 3.92% from the prior year.
- Free Cash Flow for Q1 2026 stood at $34.8 million, down from $141.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $192.8 million in Q3 2022 and bottomed at $25.7 million in Q1 2023.
- The 5-year median for Free Cash Flow is $48.6 million (2025), against an average of $78.5 million.
- The widest annual swing landed in 2023, when Free Cash Flow slumped 73.85%; it then jumped 44.43% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $192.8 million in 2022, then tumbled by 44.22% to $107.5 million in 2023, then rose by 20.11% to $129.2 million in 2024, then advanced by 9.38% to $141.3 million in 2025, then tumbled by 75.38% to $34.8 million in 2026.
- The last three Free Cash Flow figures came in at $34.8 million (Q1 2026), $141.3 million (Q3 2025), and $44.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 34.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.79 Mn |
| Mar 31, 2026 | 34.79 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Sep 30, 2024 | 129.18 Mn |
| Sep 30, 2024 | 129.18 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Sep 30, 2023 | 107.55 Mn |
| Sep 30, 2023 | 107.55 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Mar 31, 2023 | 25.65 Mn |
| Mar 31, 2023 | 25.65 Mn |
| Sep 30, 2022 | 192.79 Mn |
| Sep 30, 2022 | 192.79 Mn |
| Jun 30, 2022 | 79.02 Mn |
| Jun 30, 2022 | 79.02 Mn |
| Mar 31, 2022 | 98.09 Mn |
| Mar 31, 2022 | 98.09 Mn |
| Sep 30, 2021 | 265.43 Mn |
| Sep 30, 2021 | 265.43 Mn |
| Jun 30, 2021 | 84.61 Mn |
| Jun 30, 2021 | 84.61 Mn |
| Mar 31, 2021 | 84.11 Mn |
| Mar 31, 2021 | 84.11 Mn |
| Dec 31, 2020 | 85.28 Mn |
| Dec 31, 2020 | 85.28 Mn |
| Sep 30, 2020 | 74.56 Mn |
| Sep 30, 2020 | 74.56 Mn |
| Jun 30, 2020 | 79.79 Mn |
| Jun 30, 2020 | 79.79 Mn |
| Mar 31, 2020 | 73.47 Mn |
| Mar 31, 2020 | 73.47 Mn |
| Dec 31, 2019 | 66.89 Mn |
| Dec 31, 2019 | 66.89 Mn |
| Sep 30, 2019 | 57.40 Mn |
| Sep 30, 2019 | 57.40 Mn |
| Jun 30, 2019 | 56.50 Mn |
| Jun 30, 2019 | 56.50 Mn |
| Mar 31, 2019 | 76.66 Mn |
| Mar 31, 2019 | 76.66 Mn |
| Dec 31, 2018 | 61.78 Mn |
| Dec 31, 2018 | 61.78 Mn |
| Sep 30, 2018 | 60.12 Mn |
| Sep 30, 2018 | 60.12 Mn |
| Jun 30, 2018 | 51.73 Mn |
| Jun 30, 2018 | 51.73 Mn |
| Mar 31, 2018 | 49.91 Mn |
| Mar 31, 2018 | 49.91 Mn |
| Dec 31, 2017 | 47.86 Mn |
| Dec 31, 2017 | 47.86 Mn |
| Sep 30, 2017 | 43.49 Mn |
| Sep 30, 2017 | 43.49 Mn |
| Jun 30, 2017 | 22.64 Mn |
| Jun 30, 2017 | 22.64 Mn |
| Mar 31, 2017 | 27.76 Mn |
| Mar 31, 2017 | 27.76 Mn |
| Dec 31, 2016 | 21.06 Mn |
| Dec 31, 2016 | 21.06 Mn |
| Sep 30, 2016 | 19.95 Mn |
| Sep 30, 2016 | 19.95 Mn |
| Jun 30, 2016 | 12.45 Mn |
| Jun 30, 2016 | 12.45 Mn |
| Mar 31, 2016 | 7.25 Mn |
| Mar 31, 2016 | 7.25 Mn |
| Dec 31, 2015 | 6.92 Mn |
| Dec 31, 2015 | 6.92 Mn |
| Sep 30, 2015 | 2.66 Mn |
| Sep 30, 2015 | 2.66 Mn |
| Jun 30, 2015 | 2.17 Mn |
| Jun 30, 2015 | 2.17 Mn |
| Mar 31, 2015 | -1.62 Mn |
| Mar 31, 2015 | -1.62 Mn |
| Dec 31, 2014 | -4.74 Mn |
| Dec 31, 2014 | -4.74 Mn |
| Sep 30, 2014 | -21.07 Mn |
| Sep 30, 2014 | -21.07 Mn |
| Jun 30, 2014 | -53.34 Mn |
| Jun 30, 2014 | -53.34 Mn |
| Mar 31, 2014 | -52.26 Mn |
| Mar 31, 2014 | -52.26 Mn |
| Dec 31, 2013 | -41.04 Mn |
| Dec 31, 2013 | -41.04 Mn |
| Sep 30, 2013 | -41.55 Mn |
| Sep 30, 2013 | -41.55 Mn |
| Jun 30, 2013 | -17.38 Mn |
| Jun 30, 2013 | -17.38 Mn |
| Mar 31, 2013 | -32.37 Mn |
| Mar 31, 2013 | -32.37 Mn |
| Dec 31, 2012 | -24.51 Mn |
| Dec 31, 2012 | -24.51 Mn |
| Sep 30, 2012 | -28.13 Mn |
| Sep 30, 2012 | -28.13 Mn |
| Jun 30, 2012 | -35.03 Mn |
| Jun 30, 2012 | -35.03 Mn |
| Mar 31, 2012 | -42.43 Mn |
| Mar 31, 2012 | -42.43 Mn |
| Dec 31, 2011 | -26.26 Mn |
| Dec 31, 2011 | -26.26 Mn |
| Sep 30, 2011 | -19.29 Mn |
| Sep 30, 2011 | -19.29 Mn |
| Jun 30, 2011 | -19.14 Mn |
| Jun 30, 2011 | -19.14 Mn |
| Mar 31, 2011 | -27.27 Mn |
| Mar 31, 2011 | -27.27 Mn |
| Dec 31, 2010 | -15.65 Mn |
| Dec 31, 2010 | -15.65 Mn |
| Sep 30, 2010 | -19.34 Mn |
| Sep 30, 2010 | -19.34 Mn |